A First-in-Human Study With XAB05 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

May 19, 2022

Study Completion Date

May 19, 2022

Conditions

Infection, Bacterial

Interventions

BIOLOGICAL

Experimental

Participants will receive a single IV infusion in a double blind manner

Trial Locations (1)

QPS Netherlands B.V., Groningen

All Listed Sponsors

collaborator

QPS Netherlands B.V.

INDUSTRY

lead

Xenothera SAS

INDUSTRY